( n governmental oversight of pharmaceuti...)New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension,Health

n governmental oversight of pharmaceutical product development; the future scope of our patent coverage or that of third parties; the effects of any future litigation; general economic and business conditions, both internationally and within our industry, including exchange rate variations; and our future financing plans.

-- Ends --

For further information please contact

Nick Miles Director Communications & Investor Relations Speedel Hirschgässlein 11 CH - 4051 Basel Switzerland

T +41 (0) 61 206 40 00 D +41 (0) 61 206 40 14 F +41 (0) 61 206 40 01 M +41 (0) 79 446 25 21 E nick.miles@speedel.com www.speedel.com

Frank LaSaracina Managing Director Speedel Pharmaceuticals Inc 1661 Route 22 West P.O. Box 6532 Bridgewater, NJ 08807 United States of America

T +1 732 537 2290 F +1 732 537 2292 M +1 908 338 0501 E frank.lasaracina@speedel.com www.speedel.com

[1] Tekturna/ Rasilez ® are Novartis trademarks [2] HCTZ Hydrochlorothiazide [3] Tekturna HCT® is currently pending regulatory, including FDA, approval [4] Data on file.(Tekturna-HCT (aliskeren/hydrochlorothiazide) Combination Tablets Package Insert. March 13, 2007) [5] Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, and Angiotension-converting Enzyme Inhibitor, or an Angiotensin Recpetor Blocker Eoin O'Brien, John Barton, Juerg Nussberger, David Mulcahy, Chris Jensen, Patrick Dicker, Alice Stanton. Hypertension. 2007, 49,276-284 [6] Angiotensin Converting Enzyme Inhibitor [7] Calcium Channel Blocker [8] Diovan® is a Novartis Trademark [9] Angiotensin Receptor Blocker [10] Joint National Committee on prevention, detection, evaluation, and treatment of high b
'"/>

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
4. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
5. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
6. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
7. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
8. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
9. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
10. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development